Copyright
©The Author(s) 2020.
World J Clin Cases. Apr 26, 2020; 8(8): 1424-1443
Published online Apr 26, 2020. doi: 10.12998/wjcc.v8.i8.1424
Published online Apr 26, 2020. doi: 10.12998/wjcc.v8.i8.1424
Table 13 Overall survival depending on the combination of administered antibodies in first- and second-line chemotherapy
| First line | Second line | Median OS (mo) | P value |
| Bevacizumab | Bevacizumab | 58.4 | P = 0.693 |
| Panitumumab | Bevacizumab | 44.9 | |
| Bevacizumab | Panitumumab | 51.7 | |
| Panitumumab | Panitumumab | 46.7 | |
| Bevacizumab | Aflibercept | 44.0 | |
| Panitumumab | Aflibercept | 62.3 |
- Citation: Kalantzis I, Nonni A, Pavlakis K, Delicha EM, Miltiadou K, Kosmas C, Ziras N, Gkoumas K, Gakiopoulou H. Clinicopathological differences and correlations between right and left colon cancer. World J Clin Cases 2020; 8(8): 1424-1443
- URL: https://www.wjgnet.com/2307-8960/full/v8/i8/1424.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i8.1424